Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ADMA Biologics Inc (ADMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ADMA Biologics Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while ADMA Biologics Inc trades at $9.81 (market cap $2.22B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.3× ADMA Biologics Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ADMA | |
|---|---|---|
Market Cap | $5.07B | $2.22B |
Sector | Health | Health |
52-Week High | $29.41 | $20.38 |
52-Week Low | $20.06 | $7.60 |
Enterprise Value | $4.19B | $2.29B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →
